Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top
Weight-loss drugmakers report strong earnings: Boon or bane?
Views 119K Contents 245

On watch for tomorrow!

$CareDx(CDNA.US)$ Check out these highlights! ((.  Reported revenue of $67.2 million, an increase of 7% over the second
quarter of 2023, excluding approximately $7.8 million related to Medicare
claims billing that were held over from the first quarter of 2023 and
recognized in second quarter 2023 revenue.
--  Grew Testing Services patient results to 38,400, an increase of 2%
compared to the second quarter of 2023.
--  Achieved revenue of $9.9 million for Digital Solutions and $9.5 million
for Products, representing year-over-year growth of 33% for both
businesses.
--  Achieved the fourth consecutive quarter of collections at over 100% of
revenue for Testing Services; collected over $22 million in incremental
cash in the past four quarters.
--  Maintained a strong balance sheet, with $268.2 million in cash and cash
equivalents, and marketable securities, with no debt.
--  Received Medicare coverage for HeartCare(TM) and AlloSure(R) Lung.
--  Raised revenue guidance to $274 to $278 million for the full year
2023.
--  SEC has concluded its inquiry and does not intend to recommend an
enforcement action against the Company.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
+0
Translate
Report
3280 Views
Comment
Sign in to post a comment
    1743Followers
    28Following
    20KVisitors
    Follow